C Cordon-Cardo

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc High-resolution characterization of the pancreatic adenocarcinoma genome
    Andrew J Aguirre
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:9067-72. 2004
  2. ncbi Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control
    Eva Hernando
    Department of Pathology, Memorial Sloan Kettering Cancer Center New York, New York 10021, USA
    Nature 430:797-802. 2004
  3. ncbi Genetic and molecular markers of urothelial premalignancy and malignancy
    C Cordon-Cardo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Scand J Urol Nephrol Suppl . 2000
  4. ncbi Genetic studies and molecular markers of bladder cancer
    C Cordon-Cardo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Surg Oncol 13:319-27. 1997
  5. ncbi Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma
    C Cordon-Cardo
    Memorial Sloan Kettering Cancer, New York, NY 10021, USA
    J Natl Cancer Inst 90:1284-91. 1998
  6. ncbi Applications of molecular diagnostics: solid tumor genetics can determine clinical treatment protocols
    C Cordon-Cardo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mod Pathol 14:254-7. 2001
  7. ncbi A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:3215-20. 2007
  8. ncbi Ku70: a candidate tumor suppressor gene for murine T cell lymphoma
    G C Li
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cell 2:1-8. 1998
  9. ncbi Role of PML in cell growth and the retinoic acid pathway
    Z G Wang
    Department of Human Genetics and Molecular Biology Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Science 279:1547-51. 1998
  10. ncbi Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors
    A Hoos
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:3171-5. 2001

Collaborators

Detail Information

Publications123 found, 100 shown here

  1. pmc High-resolution characterization of the pancreatic adenocarcinoma genome
    Andrew J Aguirre
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:9067-72. 2004
    ..Thus, the integration of DNA and RNA profiles provides a highly productive entry point for the discovery of genes involved in the pathogenesis of pancreatic adenocarcinoma...
  2. ncbi Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control
    Eva Hernando
    Department of Pathology, Memorial Sloan Kettering Cancer Center New York, New York 10021, USA
    Nature 430:797-802. 2004
    ....
  3. ncbi Genetic and molecular markers of urothelial premalignancy and malignancy
    C Cordon-Cardo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Scand J Urol Nephrol Suppl . 2000
    ....
  4. ncbi Genetic studies and molecular markers of bladder cancer
    C Cordon-Cardo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Surg Oncol 13:319-27. 1997
    ..The implementation of objective predictive assays to identify these alterations in clinical material will enhance our ability to assess tumor biological activities and to design effective treatment regimes...
  5. ncbi Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma
    C Cordon-Cardo
    Memorial Sloan Kettering Cancer, New York, NY 10021, USA
    J Natl Cancer Inst 90:1284-91. 1998
    ..This study was undertaken to identify and to assess potential alterations of p27KIP1 gene expression in patients with benign prostatic hyperplasia (BPH) and patients with prostate cancer...
  6. ncbi Applications of molecular diagnostics: solid tumor genetics can determine clinical treatment protocols
    C Cordon-Cardo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mod Pathol 14:254-7. 2001
    ..The molecular characterization therefore has an important prognostic and practical role in diagnosis...
  7. ncbi A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:3215-20. 2007
    ..In this study, we aim to evaluate the SNP309 in bladder cancer and to link it to TP53 status...
  8. ncbi Ku70: a candidate tumor suppressor gene for murine T cell lymphoma
    G C Li
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cell 2:1-8. 1998
    ..These findings directly demonstrate that Ku70 deficiency facilitates neoplastic growth and suggest a novel role of the Ku70 locus in tumor suppression...
  9. ncbi Role of PML in cell growth and the retinoic acid pathway
    Z G Wang
    Department of Human Genetics and Molecular Biology Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Science 279:1547-51. 1998
    ..These results indicate that PML is a critical component of the RA pathway and that disruption of its activity by the PML-RARalpha fusion protein may be important in APL pathogenesis...
  10. ncbi Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors
    A Hoos
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:3171-5. 2001
    ..pRB and Ki-67 status may be useful to predict recurrence in certain subsets of patients...
  11. ncbi Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
    C Cordon-Cardo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021
    Cancer Res 54:794-9. 1994
    ..The overexpression of p53 and mdm2 proteins in the nuclei of tumor cells did not always correlate well with gene amplification at the mdm2 locus or mutation at the p53 gene. The possible reasons for these discrepancies are discussed...
  12. pmc Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo
    H Ouyang
    Department of Medical Physics and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Exp Med 186:921-9. 1997
    ..These results suggest that distinct but overlapping repair pathways may mediate DNA DSB repair and V(D)J recombination...
  13. ncbi Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence
    D B Agus
    Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Natl Cancer Inst 91:1869-76. 1999
    ..To understand the factors associated with regression of prostate cancers after androgen withdrawal, we studied cell cycle regulator changes in the CWR22 human prostate cancer xenograft model...
  14. pmc Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas
    H P Kourea
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Am J Pathol 155:1885-91. 1999
    ..001). Furthermore, detection of cytoplasmic p27 expression was found to be a prognostic factor for poor survival in MPNSTs (P = 0.03, relative risk = 2.4)...
  15. ncbi Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior
    D Polsky
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
    Histol Histopathol 21:743-52. 2006
    ..In this study, we examined adult soft tissue sarcomas (ASTS) to determine if alterations of pRB were associated with distinct patterns of pRB expression and clinical outcome...
  16. ncbi Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma
    R J Cote
    Department of Pathology, University of Southern California School of Medicine Norris Comprehensive Cancer Center, Los Angeles 90033, USA
    J Natl Cancer Inst 90:916-20. 1998
    ..We examined whether cellular levels of the cyclin-kinase inhibitor p27Kip1 (also known as p27) in prostate tumors could be used to predict progression of this disease...
  17. ncbi Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells
    V M Richon
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 57:2789-98. 1997
    ....
  18. ncbi Pten is essential for embryonic development and tumour suppression
    A Di Cristofano
    Department of Human Genetics, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    Nat Genet 19:348-55. 1998
    ..These results support the notion that PTEN haploinsufficiency plays a causal role in CD, LDD and BZS pathogenesis, and demonstrate that Pten is a tumour suppressor essential for embryonic development...
  19. pmc p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice
    M S Park
    Program in Molecular Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 96:6382-7. 1999
    ..Importantly, we detected both pituitary and thyroid tumors earlier in the Rb+/-p27-/- mice. We therefore propose that Rb and p27 cooperate to suppress tumor development by integrating different regulatory signals...
  20. ncbi Involvement of the Ink4a gene (p16 and p19arf) in murine tumorigenesis
    I Orlow
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Oncol 15:17-24. 1999
    ....
  21. ncbi Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma
    G H Ho
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 65:225-32. 2001
    ..Although p14ARF mutations and HDM2 gene amplification appear to be uncommon events in breast carcinoma, deregulation of this pathway may occur via alternative mechanisms in breast carcinogenesis...
  22. pmc Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation
    A Haimovitz-Friedman
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Exp Med 186:1831-41. 1997
    ..These investigations demonstrate that LPS induces a disseminated form of endothelial apoptosis, mediated sequentially by TNF and ceramide generation, and suggest that this cascade is mandatory for evolution of the endotoxic syndrome...
  23. ncbi Impaired Fas response and autoimmunity in Pten+/- mice
    A Di Cristofano
    Department of Human Genetics Molecular Biology Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10021, USA
    Science 285:2122-5. 1999
    ..These results indicate that Pten is an essential mediator of the Fas response and a repressor of autoimmunity and thus implicate the PI 3-kinase/Akt pathway in Fas-mediated apoptosis...
  24. pmc Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors
    A Hoos
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 158:1245-51. 2001
    ..Concordance of triplicate cores is high (96 to 98%) for two category distinction and decreases with the complexity of the phenotypes being analyzed (91%)...
  25. ncbi Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis
    P Santana
    Laboratory of Signal Transduction, Memorial Sloan Kettering Cancer Center New York, New York 10021, USA
    Cell 86:189-99. 1996
    ..These genetic models provide definitive evidence for the involvement of acid sphingomyelinase in one form of stress-induced apoptosis...
  26. ncbi Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models
    D B Agus
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 59:4761-4. 1999
    ..These results suggest the utility of Herceptin in the treatment of human prostate cancer...
  27. pmc Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
    K Podsypanina
    Departments of Pathology and Medicine, College of Physicians and Surgeons, Columbia University, 630 W 168th Street, P and S 14 453, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 96:1563-8. 1999
    ..Taken together, these data suggest that PTEN is a regulator of apoptosis and proliferation that behaves as a "landscaper" tumor suppressor in the gut and a "gatekeeper" tumor suppressor in other organs...
  28. pmc The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest
    S Wang
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 and Los Alamos National Laboratory, Los Alamos, NM 87545, USA
    Proc Natl Acad Sci U S A 97:1584-8. 2000
    ..Whereas Atm selects for cell-cycle arrest but not apoptosis, DNA-PKcs selects for apoptosis but not cell-cycle arrest...
  29. ncbi Intranuclear compartmentalization of cyclin E during the cell cycle: disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer
    G Juan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:1220-6. 2001
    ..These observations suggest that the nucleolus mediates a cyclin E "shuttling" between the nucleus and the cytoplasm that is probably involved in its regulation and that this mechanism could be disrupted in bladder cancer...
  30. ncbi Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer
    C I Rivas
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 91:1037-43. 1998
    ..These findings imply that both hyperplastic and neoplastic prostatic tissues may be responsive to GM-CSF...
  31. ncbi Identifying site-specific metastasis genes and functions
    G P Gupta
    Cancer Biology and Genetics Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cold Spring Harb Symp Quant Biol 70:149-58. 2005
    ..These findings improve our understanding of metastatic progression, facilitate the interpretation of primary tumor gene expression data, and open several important possibilities for future clinical application...
  32. ncbi Cigarette smoking and chromosome 9 alterations in bladder cancer
    Z F Zhang
    Department of Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Epidemiol Biomarkers Prev 6:321-6. 1997
    ....
  33. ncbi Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer
    G Dalbagni
    Urology Service, Department of Surgery, Laboratories of Developmental Hematopoiesis, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 3:1593-8. 1997
    ..The TRAP assay is reproducible, highly specific, and not dependent on the expertise of the cytopathologist. These results suggest that this assay should be further investigated as a diagnostic tool for bladder cancer...
  34. pmc Role of promyelocytic leukemia (PML) protein in tumor suppression
    E M Rego
    Department of Human Genetics and Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Exp Med 193:521-29. 2001
    ....
  35. ncbi Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer
    E Hernando
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 95:223-7. 2001
    ..These results suggest that mutations of the hsMAD2, hBUB1 and hBUB3 genes are very rare in bladder tumors and that hsMAD2 alterations are also infrequent in soft-tissue sarcomas and hepatocellular carcinomas...
  36. pmc Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation
    A N Houghton
    Memorial Sloan Kettering Cancer Center, New York 10021
    J Exp Med 167:197-212. 1988
    ..These studies demonstrate that ADAbp expression is lost with malignant transformation of melanocytes, presumably at an early stage in the transformation process...
  37. ncbi Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal
    D B Agus
    Department of Medicine and Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 58:3009-14. 1998
    ..The results suggest that serial monitoring of DOG accumulation using PET scanning may be useful as an early indicator of treatment efficacy and other outcome measures in prostate cancer...
  38. ncbi Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
    A Di Cristofano
    Department of Human Genetics, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, New York, USA
    Nat Genet 27:222-4. 2001
    ..Our findings reveal the crucial relevance of the combined tumor-suppressive activity of Pten and p27(Kip1) through the control of cell-cycle progression...
  39. ncbi Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study
    G Dalbagni
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 7:2797-801. 2001
    ..We postulated that if tumor cells at different points in the natural history of the disease contain an identical mutation in the TP53 gene, this pattern could provide evidence for the monoclonality of the recurrent bladder tumors...
  40. ncbi Alterations of cell cycle regulators affecting the RB pathway in nonfamilial retinoblastoma
    M Orjuela
    Department of Pediatrics and School of Public Health, Columbia University, New York, NY 10021, USA
    Hum Pathol 32:537-44. 2001
    ..Thus, the inclusion of molecular markers may become useful adjuncts to clinicopathological staging and subsequent determination of therapy...
  41. pmc Mzf1 controls cell proliferation and tumorigenesis
    M Gaboli
    Molecular Biology Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, New York 10021, USA
    Genes Dev 15:1625-30. 2001
    ..These findings demonstrate that Mzf1 can act as a tumor/growth suppressor in the hemopoietic compartment...
  42. ncbi Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations
    A Hoos
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Lab Invest 81:1331-8. 2001
    ..These approaches offer the opportunity to conduct pilot and validation studies of potential targets using clinical samples linked to clinicopathological databases...
  43. ncbi Expression of ras proto-oncogene proteins in normal human tissues
    M E Furth
    DeWitt Wallace Research Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021
    Oncogene 1:47-58. 1987
    ..The observed distribution of p21ras suggests a role for these proteins both in cellular proliferation and in certain specialized cellular functions...
  44. ncbi Expression of c-kit and kit ligand proteins in normal human tissues
    A Lammie
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    J Histochem Cytochem 42:1417-25. 1994
    ..In the central nervous system, KL expression was confined to Golgi and Purkinje cells in the cerebellum. These results suggest a role for this receptor and its ligand in the maintenance of a variety of fully differentiated tissues...
  45. ncbi Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase
    L M Butler
    Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 7:962-70. 2001
    ..CONCLUSIONS: The findings suggest that pyroxamide may be a useful agent for the treatment of malignancy and that induction of p21/WAF1 in transformed cells by pyroxamide may contribute to the antitumor effects of this agent...
  46. ncbi HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer
    I Osman
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 7:2643-7. 2001
    ..It also emphasizes the importance of characterizing tumors at determined points in the natural or treated history of prostate cancer when targeting treatment to specific biological processes...
  47. ncbi Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts
    E Kikuchi
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Gene Ther 14:279-86. 2007
    ....
  48. ncbi HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma
    D Polsky
    Ronald O. Perelman Department of Dermatology, New York University School of Medicine/Veterans Affairs Medical Center, New York, New York 10016, USA
    Cancer Res 61:7642-6. 2001
    ..HDM2 amplification occurs infrequently, and other mechanisms that up-regulate HDM2 expression are under investigation...
  49. ncbi Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment
    F C Maluf
    The Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, New York, USA
    Ann Oncol 17:1677-86. 2006
    ..Both individual and cooperative effects of these gene products may affect the biological behavior of primary bladder cancers and long-term outcome to standard therapy...
  50. ncbi Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract
    B Pasche
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 58:2727-32. 1998
    ..The clinical and biological significance of TbetaR-I(6A) homozygosity needs to be further investigated...
  51. pmc Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice
    E D Reis
    Departments of Surgery, Medicine, and Pathology, and Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 97:12764-9. 2000
    ..These results demonstrate sulindac reduces neointimal formation in both normolipidemic and hyperlipidemic settings and raise the possibility that similar benefits may be obtained in patients undergoing angioplasty and related procedures...
  52. ncbi Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice
    F Paris
    Laboratory of Signal Transduction and, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Science 293:293-7. 2001
    ..This study provides a basis for new approaches to prevent radiation damage to the bowel...
  53. pmc Applications of array technology: identification of molecular targets in bladder cancer
    M Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Cancer 89:2172-7. 2003
    ..This review summarizes bladder cancer studies dealing with both in vitro models and clinical specimens, using distinct microarray platforms for target discovery...
  54. pmc MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9
    A Y Jia
    Department of Pathology and Cell Biology, Columbia University, 1130 St Nicholas Avenue, New York, NY 10032, USA
    Br J Cancer 110:2945-54. 2014
    ..Despite the association of several miRNAs with bladder cancer, little is known about the miRNAs that contribute to bladder cancer progression from non-muscle invasive (NMI) to muscle-invasive (MI) disease...
  55. pmc GAB2 induces tumor angiogenesis in NRAS-driven melanoma
    Y Yang
    Department of Dermatology, Columbia University, New York, NY 10032, USA
    Oncogene 32:3627-37. 2013
    ..In conclusion, our findings provide evidence that GAB2 is a novel regulator of tumor angiogenesis in NRAS-driven melanoma through regulation of HIF-1α and VEGF expressions mediated by RAS-RAF-MEK-ERK signaling. ..
  56. ncbi Blood group-related antigens in human germ cell tumors
    R J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer Res 48:5342-7. 1988
    ..If so, it is possible that the heterogeneous expression of blood group substances in seminomas with atypical histologies is an indication of differentiation towards nonseminomatous germ cell tumor...
  57. ncbi Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell
    J Mora
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:6892-8. 2001
    ....
  58. ncbi Evaluation of alterations in the tumor suppressor genes INK4A and INK4B in human bladder tumors
    I Orlow
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Methods Mol Biol 179:43-59. 2002
  59. pmc A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas
    E Hernando
    Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncogene 28:2425-35. 2009
    ..05). Finally, treatment with a ChoKalpha-specific inhibitor resulted in a significant inhibition of tumor growth (P=0.02) and in a relevant increase in survival (P=0.03)...
  60. pmc The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues
    J Dalmau
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    Am J Pathol 141:881-6. 1992
    ..In lung tumors, the Hu antigen is restricted in its expression to all small cell carcinomas. A few other neuroendocrine-related tumors, especially neuroblastomas (50%), also express the antigen...
  61. ncbi High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas
    A Hoos
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Cancer 92:869-74. 2001
    ....
  62. ncbi Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays
    C V Hedvat
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mod Pathol 14:1270-6. 2001
    ..High levels of MDC expression were specific to CHD cases because only low levels of MDC were observed in a minor subset of LPHD, NHL or normal lymphoid tissues...
  63. pmc Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas
    M S Karpeh
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Br J Cancer 72:986-91. 1995
    ..It is postulated that RB alterations are primary events in human sarcomas and may be involved in tumorigenesis or early phases of tumour progression in these neoplasias...
  64. pmc Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer
    Z F Zhang
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Cancer 71:888-93. 1995
    ..The results suggest that p53 overexpression may be related to genetic predisposition to colorectal cancer, and p53-positive and p53-negative colorectal cancers may be controlled by different aetiological pathways...
  65. pmc Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays
    Axel Hoos
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 160:175-83. 2002
    ..Molecular alterations in the p53 pathway play a role in Hürthle cell tumorigenesis, but other unidentified molecular changes seem to be required to induce the malignant phenotype...
  66. ncbi Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods
    Ming Lan Lu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:171-9. 2002
    ..015), and it appears to be a significant prognostic factor associated with patient survival...
  67. ncbi p63 expression profiles in human normal and tumor tissues
    Charles J Di Como
    Division of Molecular Pathology, Department of Pathology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 8:494-501. 2002
    ..The p63 gene, located on chromosome 3q27-28, is a member of the p53 gene family. The product encoded by the p63 gene has been reported to be essential for normal development...
  68. ncbi Adrenocortical carcinoma: clinical, morphologic, and molecular characterization
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:941-50. 2002
    ..To define multimolecular phenotypes of adrenocortical carcinoma (ACC) and to correlate outcome with morphologic and molecular parameters...
  69. ncbi Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:679-83. 2002
    ..To evaluate the safety and pharmacokinetics of BCL-2 antisense oligonucleotide (G3139) administered by prolonged i.v. infusion in patients with advanced cancer...
  70. ncbi Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma
    José M García-Castellano
    Orthopaedic Surgery Service, affiliated with Weil Medical College of Cornell University, New York, NY 10021, USA
    Clin Cancer Res 8:782-7. 2002
    ..The aim of this study was to investigate the frequency of molecular alterations in MTAP in osteosarcoma...
  71. pmc The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147
    Marc Ladanyi
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 160:1215-21. 2002
    ..The possible basis for the overproduction or impaired surface localization of these proteins in ASPS remains unclear...
  72. ncbi Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression
    Monika Korabiowska
    Department of Cytopathology, University of Gottingen, Germany
    Mod Pathol 15:426-33. 2002
    ..To summarize, earlier phases of melanoma progression seem to be connected with the loss of expression of Ku proteins. Metastatic spread is related to dysregulation of the Ku70 and Ku80 axis...
  73. ncbi Decreased expression of Ku70/Ku80 proteins in malignant melanomas of the oral cavity
    Monika Korabiowska
    Department of Cytopathology, University of Gottingen, Germany
    Anticancer Res 22:193-6. 2002
    ..05). We conclude that decreased Ku70/80 expression in malignant melanomas of the oral cavity and loss of correlation between these markers may influence progression of oral melanomas...
  74. ncbi Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent
    Iman Osman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2980-7. 2002
    ..To identify the role of p53 pathway alteration(s) as predictors of treatment outcome in patients with advanced, resectable, squamous cell carcinoma (SCC) of the larynx and pharynx treated with larynx preservation (LP) intent...
  75. pmc Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas
    Bhuvanesh Singh
    Laboratory of Epithelial Cancer Biology, The Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 161:365-71. 2002
    ..6; 95% confidence interval = 1.9 to 29.6). The findings suggest that the 3q copy number status is an important marker for tumor progression and prognostication in patients with head and neck squamous cell carcinoma...
  76. ncbi Allotype imbalance or microsatellite mutation in low-grade soft tissue sarcomas of the extremities in adults
    Nam Hoon Cho
    Department of Pathology, Yonsei University College of Medicine, Seodaemoon ku, Shinchon dong, Seoul, Korea
    J Pathol 198:21-9. 2002
    ..In conclusion, whereas microsatellite mutation seems an uncommon event during the evolution of low-grade fibrosarcoma of the extremities in adults, the loss of DNA-PKcs defines a biologically more aggressive subset...
  77. pmc Loss of p63 expression is associated with tumor progression in bladder cancer
    Marshall J Urist
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 161:1199-206. 2002
    ..These data indicate that in contrast to the skin and prostate, p63 is not required for formation of a bladder epithelium but is indispensable for the specific differentiation of a transitional urothelium...
  78. ncbi Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:6973-80. 2002
    ..However, it appears that deregulation of cell adhesion is a common event associated with tumor progression in uroepithelial neoplasms...
  79. ncbi Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis
    Axel Hoos
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3841-9. 2002
    ..This study evaluates such molecular phenotypes with regard to cell cycle regulation and proliferation and determines their significance for patient outcome...
  80. ncbi p27 deficiency desensitizes Rb-/- cells to signals that trigger apoptosis during pituitary tumor development
    Carmen Carneiro
    Department of Molecular Biology, Menmorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Oncogene 22:361-9. 2003
    ..From these studies, we concluded that the absence of p27 disabled the trigger for an Arf-dependent apoptotic response in Rb-/- tumor cells. This suggests a novel mechanism by which the loss of p27 may impact on tumor development...
  81. pmc Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 162:609-17. 2003
    ..A potential tumor suppressor role in bladder cancer was revealed for KiSS-1. Moreover, it showed predictive value by identifying patients with poor outcome...
  82. ncbi Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer
    Mithat Gonen
    Departments of Epidemiology and Biostatistics, Medicine, Surgery, and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:406-12. 2003
    ....
  83. ncbi Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 34:54-64. 2003
    ..The molecular phenotype, p27(+)Bcl-2(+)Ki-67(-)mdm2(+), appears to be unique to nonmalignant parathyroid tumors, and multimarker phenotypes are more complex in carcinomas...
  84. ncbi p27 as a target for cancer therapeutics
    Stacy W Blain
    Department of Cell Biology and Genetics, Memorial Sloan Kettering Cancer Institute, 1275 York Avenue, New York, NY 10021, USA
    Cancer Cell 3:111-5. 2003
  85. ncbi Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes
    Marta Sanchez-Carbayo
    Memorial Sloan Kettering Cancer Center, Albert Einstein College of Medicine, York, New York 10021, USA
    Lab Invest 83:507-17. 2003
    ..This study further elucidates the genetic events associated with MDR1 expression and identifies novel targets associated with multidrug resistance...
  86. ncbi Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling
    Neil H Segal
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:1775-81. 2003
    ..CCS/MSP also has typical melanoma features, including immunoreactivity for S100 and HMB45, pigmentation, MITF-M expression, and a propensity for regional lymph node metastases...
  87. ncbi Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas
    Anna Colomer
    BIOPAT, Grup Assistencia, Barcelona, Spain
    Appl Immunohistochem Mol Morphol 11:130-7. 2003
    ..It is thus concluded that molecular profiling should be conducted in parallel with immunophenotyping when analyzing colorectal tumors for p53 status...
  88. ncbi Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients
    Marija Drobnjak
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 9:2613-9. 2003
    ..The abundance of p27, an inhibitor of cell proliferation, is controlled by Skp2-dependent proteolysis...
  89. pmc Gene discovery in bladder cancer progression using cDNA microarrays
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 163:505-16. 2003
    ..The present study has identified molecular biomarkers of potential clinical significance and critical molecular targets associated with bladder cancer progression...
  90. ncbi Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10021, USA
    Oncogene 22:5298-305. 2003
    ..Nuclear myopodin expression in the context of cell-cycle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of myopodin in bladder cancer...
  91. pmc p73alpha regulation by Chk1 in response to DNA damage
    Susana Gonzalez
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Cell Biol 23:8161-71. 2003
    ..Our data indicate a novel biochemical pathway through which the p73alpha proapoptotic function requires DNA damage-triggered p73alpha phosphorylation by Chk1...
  92. ncbi Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia
    Carmela Gurrieri
    Molecular Biology Program and Department of Pathology, Memorial Sloan Kettering Cancer Center, Sloan Kettering Division, Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Blood 103:2358-62. 2004
    ..Complete functional loss of PML is therefore selected by the APL phenotype and associates with poor prognosis and RA unresponsiveness...
  93. ncbi Comparison of gene expression profiles in laser-microdissected, nonembedded, and OCT-embedded tumor samples by oligonucleotide microarray analysis
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Clin Chem 49:2096-100. 2003
  94. ncbi p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer
    Pere Puig
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:5642-51. 2003
    ..To characterize the expression profile of p73 in human normal tissues by immunohistochemistry (IHC) and to analyze the correlation between p73 expression and bladder cancer progression...
  95. pmc Pten dose dictates cancer progression in the prostate
    Lloyd C Trotman
    Molecular Biology Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, New York, USA
    PLoS Biol 1:E59. 2003
    ..Our results provide conclusive genetic support for the notion that PTEN is haploinsufficient in tumor suppression and that its dose is a key determinant in cancer progression...
  96. ncbi Loss of the tumor suppressor PML in human cancers of multiple histologic origins
    Carmela Gurrieri
    Molecular Biology Program and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 96:269-79. 2004
    ..However, its role in the pathogenesis of human cancers other than APL is still unclear. We therefore assessed the status and expression of the PML gene in solid tumors of multiple histologic origins...
  97. ncbi p53 and RB: simple interesting correlates or tumor markers of critical predictive nature?
    Carlos Cordon-Cardo
    J Clin Oncol 22:975-7. 2004
  98. ncbi Application of new in situ hybridization probes for Ku70 and Ku80 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemical analysis
    Monika Korabiowska
    Department of Cytopathology, Georg August University, Goettingen, Germany
    Hum Pathol 35:210-6. 2004
    ..The laboratory procedure is much more complicated than the immunohistochemical method, however...
  99. ncbi Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development
    Gloria E Mao
    Department of Epidemiology, School of Public Health, University of California Los Angeles, Los Angeles, CA, USA
    Cancer Epidemiol Biomarkers Prev 13:383-90. 2004
    ..These findings suggest that chemoprevention strategies with retinoids may be most effective if applied during the early stages of transformation...
  100. ncbi Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer
    Daniel E H Afar
    Protein Design Labs, Inc, 34801 Campus Drive, Fremont, CA 94555, USA
    Mol Cancer Ther 3:921-32. 2004
    ..These data support the further evaluation and clinical testing of huPr1-vcMMAE as a novel therapeutic for the treatment of metastatic and hormone-resistant prostate cancer...